MedTrace Logo

Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated Pneumonia

NCT00610623 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2008-02-08

No results posted yet for this study

Summary

The purpose of this study is to assess the clinical efficacy of azithromycin, used as a quorum-sensing blocker, when compared to placebo for preventing or delaying the occurrence of pneumonia in ventilated patients colonized with Pseudomonas aeruginosa.

Conditions

  • Pneumonia, Ventilator-Associated
  • Pseudomonas Infections

Interventions

DRUG

azithromycin

300 mg/day, IV from day 1 to 20

DRUG

placebo

once per day, IV from day 1 to 20

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • Anbics Management-Services Ag

    lead INDUSTRY

Principal Investigators

  • Christian Van Delden, MD · Service of Infectious Diseases, University Hospital Geneva, Switzerland

  • Jean Carlet, MD · General Intensive Care Unit, Hospital Saint-Joseph, Paris, France

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • Belgium
  • France
  • Poland
  • Serbia and Montenegro
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00610623 on ClinicalTrials.gov